Bionano Genomics (BNGO) Capital Leases (2021 - 2026)

Bionano Genomics (BNGO) has 6 years of Capital Leases data on file, last reported at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases fell 1.79% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 1.79% YoY), and the FY2025 full-year result was $3.5 million, down 1.67% from the prior year.
• Capital Leases was little changed at $3.5 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $3.6 million in Q1 2022 to a low of $3.5 million in Q1 2026.
• A 5-year average of $3.6 million and a median of $3.6 million in 2024 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases retreated 0.63% in 2022 and fell 1.79% in 2026, its largest moves.
• Tracing BNGO's Capital Leases over 5 years: stood at $3.6 million in 2022, then declined by 0.94% to $3.6 million in 2023, then declined by 1.28% to $3.5 million in 2024, then dropped by 1.67% to $3.5 million in 2025, then declined by 0.49% to $3.5 million in 2026.
• Business Quant data shows BNGO's Capital Leases at $3.5 million in Q1 2026, $3.5 million in Q4 2025, and $3.5 million in Q3 2025.